inhibitor – media

J&J buys into Bristol-Myers cardiovascular disease program

Johnson & Johnson has bought into Bristol-Myers Squibb’s Factor XIa inhibitor program. The deal gives J&J a stake in the development and potential commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.
- Source: Fiercebiotech
- 2,268
- April 19, 2018
anticoagulants inhibitor Market Views
Another immunometabolism deal? Johns Hopkins spinout Dracen lands $36M investment from Deerfield

The company, founded just a year ago, is developing novel glutamine antagonists that work as inhibitors of cancer metabolism, choking out tumors and their normal metabolic function.
- Source: Endpts
- 609
- April 3, 2018
cancer inhibitor Market Views metabolism
Cancer Researck UK links with Ideaya on PARG inhibitors

Cancer Research UK is partnering with US biotech Ideaya Biosciences to develop small molecule inhibitors of Poly(ADP-ribose) glycohydrolase (PARG).
- Source: pharmatimes
- 498
- March 15, 2018
glycohydrolase inhibitor Market Views
Merck’s ERK inhibitor shows promise in combo against resistant cancers

One-fifth of patients in a phase 1 study responded to an investigational ERK inhibitor from Merck, bolstering hopes that this type of drug could be used effectively in combination with other cancer drugs. ERK is a cell signal that is believed to drive the growth of many cancers.
- Source: fiercebiotech
- 554
- February 23, 2018
cancer drugs Company Insight inhibitor
Genentech’s Tecentriq Impresses Again in Late-Stage Kidney Cancer Trial

Genentech’s PD-L1 inhibitor Tecentriq continues to show off its versatility. Monday, the Roche subsidiary announced a combination of Tecentriq and Avastin (bevacizumab) was significantly beneficial to patients with advanced or metastatic renal cell carcinoma (mRCC) who have not received prior systemic active or experimental therapy.
- Source: Biospace
- 666
- February 11, 2018
Clinical Trial inhibitor mRCC Tecentriq
the Mayo Clinic experience

Immune checkpoint inhibitors have revolutionized the treatment of advanced malignancies. By blocking T-cell inhibition these drugs result in immune targeting of tumor cells and normal tissue. As such, their main toxicity is inducing immune-mediated tissue damage.
- Source: acrabstracts.org
- 497
- January 30, 2018
inhibitor malignancies Researches
AstraZeneca’s PARP Inhibitor Lynparza Gets Approval in Japan

AstraZeneca AZN and partner Merck MRK announced that the Japanese Ministry of Health, Labour and Welfare has granted approval to its PARP inhibitor, Lynparza, as a maintenance therapy for relapsed ovarian cancer, irrespective of BRCA mutation status in patients who have responded to their last platinum-based chemotherapy.
- Source: finance.yahoo
- 688
- January 26, 2018
cancer inhibitor New Approvals ovarian
Merck KGaA taps UK cancer research organizations to feed pipeline

After an R&D drought that lasted more than a decade, Merck KGaA may be coming out of the desert. Following two recent drug approvals, including the landmark FDA OK for checkpoint inhibitor Bavencio, the German Merck is now entering an R&D collaboration that might help fill its pipeline with new cancer drug contenders.
- Source: Endpts
- 568
- January 23, 2018
Bavencio cancer inhibitor Market Views
AstraZeneca’s PARP inhibitor gains market edge with breast cancer approval

AstraZeneca still enjoys the perks of being first to market with its PARP inhibitor. Lynparza (olaparib) sales were $81 million from July to September, whereas net revenues were $16.8 million and $39.4 million for Clovis Oncology Inc.'s Rubraca (rucaparib) and Tesaro Inc.'s Zejula (niraparib), respectively.
- Source: Biopharmadive
- 590
- January 17, 2018
inhibitor Lynparza New Approvals
US awards Novartis’ Kisqali ‘Breakthrough’ status

Novartis’ CDK4/6 inhibitor Kisqali has picked up Breakthrough status in the US as an initial endocrine-based treatment in certain patients with breast cancer.
- Source: pharmatimes
- 563
- January 4, 2018
inhibitor Kisqali New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.